Company intelligence / Profile preview

GIM Biotech

Guangzhou, Guangdong, China

Ownership: Private
Development stage: Other

Overview

GIM Biotech is a clinical-stage biotechnology company focused on the development of innovative gene therapies using advanced AAV vector technology. The company utilizes a proprietary platform for AAV vector screening and optimization to enhance delivery efficiency and tissue specificity. Its pipeline targets high-impact therapeutic areas including ophthalmology, hematology, and neurology. The lead candidate, GIM-001, is currently being evaluated for the treatment of wet age-related macular degeneration. GIM Biotech is headquartered in Guangzhou, China, and is supported by prominent venture capital investors.

Therapeutic areas: HematologyNeurologyOphthalmology
Modalities: Gene therapyBiologic
Industry: Biotech

Beyond the preview

Go deeper on GIM Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GIM Biotech.

Explore the full profile